Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06UEC
|
|||
| Former ID |
DIB010504
|
|||
| Drug Name |
ADXS-HER2
|
|||
| Synonyms |
Lovaxin B; ADXS31-164; Her2/neu cancer vaccine (Listeria vector), Advaxis
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2], [3] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [4] | ||
| Company |
Advaxis Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT02386501) Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.